Revaccination with poliovirus after allogeneic stem cell transplant (SCT) is usually effective, but the longevity of this immunity is unknown. Therefore, poliovirus immunity was studied in 134 patients having survived at least 5 years after vaccination. The median follow-up from vaccination was 8 years (1-19 years). In all, 21 (15.6%) patients had become seronegative to at least one of the poliovirus serotypes during follow-up. The estimated probabilities of remaining immune to poliovirus at 5 and 10 years after vaccination were 94 and 94% for subtype 1, 98 and 94% for subtype 2, and 93 and 90% for subtype 3, respectively. In multivariate analysis, the only risk factor for loss of immunity was younger patient age (Po0.01), and there was a strong trend for patients with chronic GVHD to lose immunity more rapidly (P ¼ 0.07). A total of 14 patients received a booster dose of an inactivated poliovirus vaccine and all responded. We conclude that poliovirus immunity is retained long term after revaccination in most patients after allogeneic SCT.
term Allogeneic stem cell transplant (SCT) recipients lose immunity to poliovirus early after the transplantation. [1] [2] [3] A revaccination schedule with three doses of an inactivated poliovirus vaccine is therefore recommended both by the European Group for Blood and Marrow Transplantation (EBMT) and the CDC. 4, 5 The efficacy of a three-dose schedule is good, with most patients obtaining protective immunity. 2, 3, 6 However, whether this immunity is long lasting is unknown. The aim of this study was therefore to measure poliovirus immunity during long-term follow-up after allogeneic SCT.
Patients and methods
In all, 134 long-term survivors who underwent allogeneic SCT between 1980 and 1997 at Karolinska University Hospital, Huddinge were included in the study. Patients should have been disease free at least for 5 years after allogeneic SCT or had been reinduced into complete remission by donor lymphocyte infusions. Patient characteristics are shown in Table 1 .
The transplant procedures have changed over the years, [7] [8] [9] [10] [11] but cyclophosphamide and 10 Gy TBI or busulfan in combination with cyclophosphamide were the most common conditioning regimens used. Patients with mismatched or unrelated donors were treated with ATG in varying doses and schedules. GVHD prophylaxis was given either with methotrexate, cyclosporin A, or the combination of the two drugs. Seven patients received T-cell-depleted grafts as part of a randomized trial. 8 Patients were treated with prednisolone 2 mg/kg/day when they developed acute GVHD grade I. PUVA was added to patients responding poorly to corticosteroids. Chronic GVHD was usually treated with the combination of prednisolone and cyclosporine. However, other treatments such as photopheresis, tacrolimus, thalidomide, azathioprin, and low-dose total lymphoid irradiation were also used in patients not responding to standard therapy.
Vaccination and serology
All patients were vaccinated with a trivalent inactivated poliovirus vaccine (SBL vaccine, Stockholm, Sweden). All patients had received three doses of vaccine starting at 12 months after SCT. Patients were vaccinated regardless of whether they had ongoing chronic GVHD and/or immunosuppression. Patients losing immunity or having a very weak immunity to at least one of the poliovirus serotypes during follow-up were given one booster dose. During the first 5 years after SCT, most patients had serum samples collected yearly for determination of poliovirus immunity. Thereafter, samples were usually obtained every 18-24 months. The determination of poliovirus titers was performed by virus neutralization performed in the routine virus diagnostic laboratory. 12 Since the analyses were performed over several years, no attempt was made to analyze all samples from an individual patient at the same time. A more than two-step titer change was interpreted as significant.
Statistics
Data were analyzed as titer steps with each subsequent dilution giving an increase of one. A sample lacking antibodies to a poliovirus serotype was arbitrarily given the number one. Since not all patients had samples taken at all time points, the results from 5 and 6 years after vaccination were merged to represent 5 years. Similarly results from samples drawn at 10 and 11 years were merged to represent 10 years. A patient needing a booster dose was regarded as having lost immunity to poliovirus regardless of whether the dose was given due to seronegativity or low poliovirus titers and was censored at that time point from the analyses. For nominal variables, Kaplan-Meier estimates with the log-rank test were calculated with loss of immunity and vaccination used as events. The definition of chronic GVHD in the analyses was all grades of chronic GVHD occurring at any time after SCT vs no chronic GVHD. For continuous variables and multivariate analysis, Cox models were constructed. Antibody titers were compared by the Mann-Whitney U-test.
Results
Overall 21 of 134 (15.6%) patients had become seronegative to at least one of the poliovirus serotypes during follow-up. Six patients became seronegative to two serotypes and 15 to one serotype. A total of 14 patients received a booster dose of an inactivated poliovirus vaccine. All booster doses were effective in eliciting new immunity. The median follow-up from vaccination to either a booster dose or last available analyzed sample was 8 years (1-19 years). The estimated probabilities to remain immune to poliovirus 5 and 10 years after vaccination were 94 and 94% for subtype 1, 98 and 94% for subtype 2, and 93 and 90% for subtype 3, respectively.
The analysis of risk factors for loss of immunity was performed for poliovirus type 3, since this was the subtype for which most patients had lost immunity. Younger patient age was the only factor in univariate analysis that influenced the risk for becoming seronegative (HR 1.05; 95% CI 1.01-1.1; P ¼ 0.02). In all, 23% of children p10 years old at the time of SCT lost immunity to poliovirus type 3 compared to 12% of patients age 11-30 years and 2% of patients 430 years old at the time of SCT. There was no difference in the mean time of follow-up from SCT in the different cohorts (9.0 vs 8.7 vs 8.0 years). Acute GVHD had a borderline significant effect (HR 3.2; 95% CI 0.88-12.0; P ¼ 0.07), while donor type, stem cell source, donor age, and chronic GVHD did not influence the likelihood of becoming seronegative. In multivariate analysis, younger patient age remained significant (HR 1.06; 95% CI 1.02-1.12; Po0.01) and there was a trend for chronic GVHD to influence the risk (HR 3.1; 95% CI 0.9-10.9; P ¼ 0.07), while there was no effect by acute GVHD. There was no clear tendency for decreasing the median titers over time in the entire cohort for any subtype. The mean antibody titers for poliovirus type 3 at 5, 10, and 15 years after vaccination are shown in Figure 1 . No factor (acute GVHD, chronic GVHD, donor type, the stage of disease) affected the antibody levels (data not shown).
Discussion
Revaccination after allogeneic SCT results in protective immunity in most patients. [1] [2] [3] However, no data has been presented with regard to the durability of a postvaccination-induced immunity to poliovirus. This information is of practical importance for how often immune status should be assessed during long-term follow-up and the need for booster doses. Our results show that poliovirus immunity is durable for at least a decade in most patients. In studies of healthy adults 10-15 years after primary vaccination, the prevalence of neutralizing antibodies to poliovirus was between 90 and 99% with the lowest titers to poliovirus type 3. 13, 14 Our results are similar in adults transplanted above the age of 30 years, but the risk of losing immunity to poliovirus seems to be substantially lower in children and adolescents or young adults (67-88% at 8 years of followup, respectively). Therefore, the results show that routine checks of immunity are needed and booster vaccination might be necessary in some patients to ascertain long-term protection against poliovirus. Although we have not analyzed other specific immunities in this study, it is likely that similar results would be obtained against, for example, tetanus and diphtheria requiring boosters, especially since immunities to these agents decrease over time also in normal individuals.
The results of our analysis of risk factors revealed that GVHD, not surprisingly, was a risk factor for loss of immunity. 15 That acute GVHD was more important in univariate, while chronic GVHD was important in multivariate analysis is probably explained by the close correlation between the two events. [16] [17] [18] Surprisingly, younger patient age was associated with loss of immunity. The reason for this finding is unknown. We did analyze donor age, but this was not associated with long-term immune status. Also, the age effect was not explained by a difference in either the risk for acute or chronic GVHD. It could possibly be disease dependent since children more often are transplanted due to ALL and we have previously shown that adult patients with ALL and those with more advanced disease were more likely to being seronegative to tetanus before SCT than patients with myeloid malignancies such as AML or CML. 19 However, we could not find such a tendency in the data. We have seen a similar effect for measles immunity where also younger patients were more likely to lose immunity than older patients. 20 The most likely explanation is that younger patients have been vaccinated, while older ones have had natural measles infection probably representing a stronger antigen challenge. This can of course not be the explanation for the increased risk of losing poliovirus immunity. Thus, the cause of this inverse age effect on poliovirus immunity is unknown.
We therefore conclude that the likelihood for SCT patients of retaining poliovirus immunity during the first decade after revaccination is good, but regular controls of the immune status are necessary especially in children.
